

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/04, A01N 43/54, C07K 5/00	A1	(11) International Publication Number: WO 98/04277 (43) International Publication Date: 5 February 1998 (05.02.98)
(21) International Application Number: PCT/US97/11817 (22) International Filing Date: 8 July 1997 (08.07.97) (30) Priority Data: 08/690,013 31 July 1996 (31.07.96) US (71) Applicant: UNIVERSITY OF PITTSBURGH OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION [US/US]; 911 William Pitt Union, Pittsburgh, PA 15260 (US). (72) Inventors: LAZO, John, S.; 5128 Pembroke Place, Pittsburgh, PA 15232 (US). WIPF, Peter; 135 Techview Terrace, Pittsburgh, PA 15213 (US). (74) Agent: MEYERS, Diane, R.; Eckert Seamans Cherin & Mellott, 42nd floor, 600 Grant Street, Pittsburgh, PA 15219 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: PEPTIDYL PRODRUGS AND METHODS OF MAKING AND USING THE SAME (57) Abstract Peptidyl prodrugs of therapeutic agents having an activating function are disclosed. These therapeutic agents having activating functions include those having an amino, thiol, or hydroxyl function. Methods of making and using these prodrugs are also disclosed.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

- 1 -

PEPTIDYL PRODRUGS AND METHODS OF
MAKING AND USING THE SAME

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention relates to biologically protected peptidyl
prodrugs generally useful in the treatment of proliferative disorders and other
5 illnesses. These prodrugs represent a novel form of drug delivery that extends the
biologically active life of many therapeutic formulations. The present invention also
relates to methods of making and using these prodrugs.

2. Background of the Invention

Many therapeutic agents are limited in their use because they have an
10 abbreviated pharmacological life. The pharmacological effect of a drug is related to
the drug concentration at its site of action and the duration of drug exposure. There
is a further relationship between the concentration of a drug at its site of action and
the drug concentration in the systemic circulation. Drugs that can quickly
metabolize or become inactivated are rapidly removed from the system circulation
15 and therefore often require high doses and/or frequent administration to achieve
effective systemic levels and the desired pharmacological activity in the body. High
doses of drugs and frequent drug treatments can be costly, dangerous and
impractical. Sustained-release pharmaceutical preparations reduce these problems
while affording equivalent biological activity.

20 The present invention is generally directed to various prodrugs useful
in the treatment of, among other illnesses, leukemia. The term "prodrug" as used
herein, and as will be understood by one skilled in the art, refers to a biologically

inactive chemical compound that is converted into a biologically active agent within the body. The prodrugs of the present invention lack pharmacological activity until they are spontaneously activated in the body to form biologically active drug forms. The activated prodrugs of the present invention generally show the same efficacy in the body as the parent compounds, but provide the added advantage of having a longer active life within the body.

The prodrug concept is of particular interest for those drugs that undergo rapid metabolism in the body. An example of one such drug is ara-C, which is also known by the names cytosine arabinoside, cytarabine and 1-(β -D-arabinofuranosyl) cytosine. Ara-C is known to be an important and effective antimetabolite for use in the therapy of acute non-lymphocytic leukemia in adults and children, acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia. It is also used in the prophylaxis and treatment of meningeal leukemia and for non-Hodgkin lymphoma in both adults and children.

Ara-C is an analogue of the pyrimidine nucleosides cytidine and deoxycytidine, with an arabinose sugar moiety replacing ribose or deoxyribose. Ara-C kills cells in the DNA synthetic phase (S-phase) of the cycle by an active process called apoptosis, and functions by inhibiting DNA polymerase, the enzyme that catalyzes the formation of DNA. To function in this capacity, the drug must be activated by pyrimidine nucleoside kinases that first promote formation of the nucleotide ara-cytosine monophosphate (ara-CMP) and then convert ara-CMP to the diphosphate and triphosphate nucleotides ara-cytosine diphosphate (ara-CDP) and ara-cytosine triphosphate (ara-CTP). Accumulation of ara-CTP causes potent inhibition of DNA synthesis in many cells. Inhibition of DNA chain elongation is effected when ara-C is incorporated at the terminal position of a growing DNA chain. There is also evidence that ara-C incorporated into DNA slows DNA template function. Cell death occurs when ara-C causes continuous inhibition of DNA synthesis for a duration of at least one cell cycle, so that cells are exposed in the S-phase. The mean cell cycle time in human acute myelocytic leukemia is one to two days.

Accumulation of sufficient ara-CTP to effectively inhibit DNA synthesis is impeded by the action of two enzymes -- cytidine deaminase and dCMP deaminase. Ara-C is rapidly metabolized in the body by cytidine deaminase to form

the nontoxic metabolite arauridine (ara-U); cytosine deaminase cleaves the primary amine from ara-C thereby rendering the drug inactive. In addition, dCMP deaminase converts ara-CMP to the inactive metabolite uracil arabinoside (ara-UMP). About 80% of a given ara-C does is excreted in the urine within 24 hours, with less than 10% appearing as cytarabine; the remainder is ara-U. Accordingly, the drug must be administered by continuous infusion that requires hospitalization or frequent administration of high doses that are sometimes associated with significant untoward effects.

Use of ara-C, and derivatives thereof, in the treatment of various illnesses is known in the art. For example, U.S. Patent Nos. 3,991,045, 4,055,716 and 4,097,665 disclose N⁴-acyl-1-β-D-arabinofuranosylcytosine, N⁴-acyl-1-β-D-arabinofuranosylcytosine-5'-esters and diacylnucleosides, respectively, useful as chemotherapeutic agents in the treatment of cancer. U.S. Patent No. 4,145,414 discloses 5'-esters of aracytadine, and methods of making the same, which show sustained release of ara-C in the body. U.S. Patent No. 4,367,332 discloses N⁴-alkoxycarbonylarabinofuranosyl cytosine compounds generally useful as anti-tumor agents.

None of the above patents teach or suggest the prodrugs, or methods of making and using the same, taught by the present invention. Accordingly, there remains a very real and substantial need to provide drugs which have a longer pharmacologically active life in the body. The present invention addresses this need.

SUMMARY OF THE INVENTION

The present invention is directed to prodrug formulations of therapeutic agents having an activating function. As used herein, the term "activating function," when used in describing a therapeutic agent, refers to those therapeutic agents which contain a reactive amino function, especially a primary or secondary amine, a reactive thiol function, or a reactive hydroxyl function. The prodrugs of the present invention are generally characterized as having a peptide moiety attached to the amino, thiol or hydroxyl function of the therapeutic agent. In a preferred embodiment the peptide moiety is attached to the drug via an

azapeptide linkage. The present invention is further directed to methods of making and using these prodrugs.

5 It is an object of the present invention to provide prodrug formulations of therapeutic agents having an activating function which have an extended biologically active life.

It is a further object of the present invention to provide prodrug formulations of ara-C for use in the therapeutic treatment of illnesses.

10 It is another object of the present invention to provide methods for synthesizing prodrug formulations of therapeutic agents having an activating function.

It is yet another object of the present invention to provide methods for synthesizing prodrug formulations of ara-C.

15 It is another object of this invention to provide methods for using a therapeutically effective amount of a prodrug formulation of a therapeutic agent having an activating function in a patient.

It is a further object of this invention to provide methods of using in a patient a therapeutically effective amount of a prodrug formulation of ara-C.

20 It is a further object of this invention to provide prodrugs that can be controlled and/or altered so as to change the rate at which the prodrug becomes activated in a patient.

It is a further object of this invention to provide prodrugs that reduce or minimize the need for hospital infusion of certain therapeutic agents.

25 It is a further object of the present invention to provide prodrugs that resist or delay undesired enzymatic inactivation.

These and other objects of the invention will be more fully understood from the drawings and following description of the invention and the claims appended hereto.

BRIEF DESCRIPTION OF THE DRAWINGS

30 Figure 1 shows a schematic diagram of methods for preparing a prodrug formulation according to one embodiment of the present invention.

Figure 2 shows a schematic diagram of methods for preparing a prodrug formulation according to another embodiment of the present invention.

Figure 3 shows a schematic diagram of methods for preparing a prodrug formulation according to another embodiment of the present invention.

Figure 4 shows a schematic diagram of the methods for preparing a prodrug formulation having an azapeptide linkage according to one embodiment of the present invention.

Figure 5 shows the heterocycles which are formed upon internal cyclization of various prodrugs formulations prepared according to the present invention.

Figure 6 is a graph illustrating release of ara-C from compounds 10 and 17 in MeOH-d₄ at 22°C as monitored by ¹H NMR, determined according to the methods of Example 2.

Figure 7 is a graph illustrating release of ara-C from compounds 10, 15 and 17 in the presence of NaOAc in MeOH-d₄ at 22°C as monitored by ¹H NMR, determined according to the methods of Example 2.

Figure 8 is a graph illustrating release of ara-C from compounds 10 and 17 in the presence of HOAc in MeOH-d₄ at 22°C as monitored by ¹H NMR, determined according to the methods of Example 2.

Figure 9 is a graph plotting the percentage of human tumor cells displaying morphological evidence of active cell death, known in the art as apoptosis, over time (hours) for ara-C, compounds 10, 15, 17 and 19 and a DMSO control, determined according to the methods of Example 4.

Figure 10 is a graph plotting morphological apoptosis (%) versus concentration (μM) of preincubated ara-C and compound 19 and a DMSO control, determined according to the methods of Example 4.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

As used herein, the term "patients" refers to members of the animal kingdom including but not limited to human beings.

The present invention is directed to prodrug compositions that are generally useful in the treatment of various illnesses. As used herein, the term "illness" refers to proliferative disorders including but not limited to cancers such as leukemia, lymphomas and neoplastic meningitis.

More specifically, the present invention is directed to a prodrug having the formula:



10 wherein R is a peptide group having between about 1 and 10 amino acids, R¹ is selected from the group consisting of a carbon substituent, hydrogen, nitrogen and oxygen, Y is selected from the group consisting of carbon attached to two carbon substituents, two hydrogens or one carbon substituent and one hydrogen, nitrogen attached to a carbon substituent, and NH, and Z is a therapeutic agent having an activating function. As used herein, the term "carbon substituents" refers to alkyl, allyl, aryl or other carbon based groups.


15 Preferably, R is a peptide group having between about 1 and 5 amino acid groups and more preferably 2 amino acid groups. In the most preferred embodiment, R is a dipeptide containing an α,α -disubstituted amino acid.

20 Z can be any therapeutic agent containing an activating function, including but not limited to, antiviral nucleosides, antineoplastic agents, and purine and pyrimidine nucleotide drugs. These include but are not limited to hydroxyurea, thioguanine, mitomycin C, zalcitabine, didanosine, zidovudine and stavudine. In a preferred embodiment, Z is ara-C.

As will be understood by one skilled in the art, when Y equals NH, the prodrug contains an azapeptide linkage. An azapeptide is an amino acid residue in which the α -carbon of the amino acid has been replaced with a nitrogen.

25 As will be understood by one skilled in the art, peptides are amino acid polymers in which the individual amino acid residues are linked together by amide, or peptide, bonds. The protected peptide groups used in the present invention can be any suitable amino acid or amino acid derived groups. As used herein, the terms "suitable peptide" and "protective peptide group" refer to any peptide or peptide analogue of the general formula

30



35 wherein R¹ and Y are as defined as above, and n is between 1 and 10, which is compatible with the therapeutic agents of the present invention, and which can be

bonded thereto. Preferably, the peptide groups will contain between about 1 and 10 amino acids ($n = 1$ to 10), most preferably between about 1 and 5 amino acids ($n = 1$ to 5) and most preferably 2 amino acids ($n = 2$). The amino acids used in the peptide groups according to the present invention can be either alpha or beta type, although the alpha type is preferred. Examples of peptide groups suitable for use in the present invention include, but are not limited to, 2-aminoisobutyric acid (Aib), isovaline, 2-methylserine, *tert*-leucine, 2-methylphenylalanine, 2,2-dipropylglycine and β -alanine.

Fast degradation of certain peptides by a variety of peptidases restricts the use of peptidal derivatives of active drugs. Peptides incorporating non-proteinogenic amino acids have significantly increased stabilities towards proteolytic enzymes. The rate of cleavage of the bond between peptides with α,α -disubstituted amino acids and the therapeutic agent is significantly reduced. Acylation of the therapeutic agents of the present invention with short peptides containing α,α -dialkyl amino acids is therefore most preferred. The most preferred of these compounds is 2-aminoisobutyric acid (Aib). In addition, the presence of α,α -disubstituted amino acids significantly facilitates intramolecular cyclization reactions. As will be discussed below, it is the intramolecular cyclization reaction which causes conversion of the prodrug to the active drug form. This characteristic property can be used for the selective cleavage of the bond between peptides and the therapeutic agent.

As stated above, the prodrug concept is useful in prolonging the biologically active life of therapeutic agents which undergo a rapid metabolism in the body. An example of such therapeutic agents include those with a primary amine. An unencumbered primary amine is generally needed for biological activity. Various deaminases in the body, however, will cleave the primary amine from these therapeutic agents thereby rendering them inactive. The present inventors have discovered that protecting this primary amine with a peptide group serves to circumvent the action of the various deaminases in the body. The therapeutic agent is introduced to the body in prodrug or inactive form, which inactivation is caused by the attachment of a protective peptide group to its primary amine. This concept is equally applicable to therapeutic agents having a reactive thiol or hydroxyl function. Once in the body, the prodrug is spontaneously activated to form the

active drug. Generally, the activated prodrugs are indistinguishable from the parent compounds in both structure and function. Spontaneous activation occurs by cyclization of the peptide group, which causes the peptide group to detach from the therapeutic agent thereby yielding the active therapeutic agent and a heterocycle corresponding with the peptide group. Thus, the reactive function is free and unencumbered and the therapeutic agent is capable of functioning as an active compound.

It is a feature of the present invention that the rate of release of the biologically active drug can be altered as desired. This alteration is effected by increasing or decreasing the rate of intermolecular activate function deacylation, which is determined by the chemical composition of the peptidyl moieties attached to the activating function. In the case of ara-C, the rate of release of the biologically active ara-C depends on the rate of intramolecular N⁴-deacylation, which is determined by the chemical composition of the peptidyl moieties attached to the N⁴ position. Accordingly, the prodrugs of the present invention function as timed release formulations whose rate of release can be adjusted by modifying the structure of the peptidyl moiety attached thereto. Generally, heterocycles of rings having 5-7 members will form preferentially, and an increase in the steric bulk of the 2-substituents on the amino acid moiety will favor the activation process.

The present invention is also directed to methods for forming the prodrugs as described above. More specifically, the present invention is directed to a method for preparing a prodrug formulation of a therapeutic agent having an activating function comprising the step of bonding a protective peptide group to the activating function of said therapeutic agent. The prodrug formulation prepared

according to these methods has the general formula
$$\text{R} - \text{N} \begin{array}{c} \text{R}^1 \\ | \end{array} - \text{Y} - \text{C} \begin{array}{c} \text{O} \\ || \end{array} - \text{Z},$$
 wherein R, R¹, Y and Z are as defined above.

Optionally, the therapeutic agent can be lithiated prior to the bonding step. Lithiation is effected by mixing the therapeutic agent with a strong base containing lithium, for example, n-BuLi in hexanes, LDA or Schwesinger base. Under certain conditions, such as when the therapeutic agent has a primary amine as its activating function, lithiation of the therapeutic agent results in an increased yield of the desired prodrug.

In addition, the presence of hydroxyl groups other than the activating function on the therapeutic agent can contribute to the low solubility of the compound in common organic solvents. Conversion of the hydroxyl groups to high solubility groups is therefore an optional step prior to the bonding step, or, if lithiation is performed, prior to the lithiating step. As used herein, the term "high solubility groups" refers to those groups attached to an oxygen molecule of the therapeutic agents of the present invention, which provide the therapeutic agents with a solubility in organic solvents higher than that achieved when the hydroxyl groups are present. The hydroxyl groups can be converted to any groups which will increase the solubility of the compound, including but not limited to *tert*-butyldimethylsilyl chloride (TBDMSCl), *tert*-butyldiphenylsilyl (TBDPSCI), other silyls, acetyl chloride groups, benzoyl chloride groups or methoxy trityl groups. If using TBDMSCl, conversion of OH groups to OTBDMS groups can be accomplished by combining TBDMSCl with the therapeutic agent in the presence of imidazole, dimethyl formamide (DMF) and dimethylamino puridine (DMAP) in a reaction which takes between about 1 to 3 days, preferably 2 days, at ambient temperature. If the activating function is a hydroxyl group, selective deprotection with a mild acid, base or fluoride anion should be affected before conversion of any other hydroxyl groups on the therapeutic agent.

If the conversion step is performed as the final step of the methods, the OH groups should be restored by removal of the protective group. Removal is effected by any means known in the art including, for example, treatment with fluoride for the silyls, catalytic hydrogenation for the benzoyl groups, and hydrolysis in dilute acid for the acetyl and methoxytrityl groups.

The step of bonding a protective peptide group to the activated function of the therapeutic agent can be accomplished by conversion of a c-terminal amino acid to an oxazolinone or activation with a coupling agent. In the case of prodrugs having the azapeptide linkage, condensation of a c-terminal hydrozide with an acyl imidazole compound is preferred. For example, the therapeutic agent can be bonded to any suitable peptide by a condensation reaction performed in the presence of a coupling agent, a polar aprotic solvent and an acylation catalyst. A suitable aprotic solvent for use in the methods of the present invention is

5 tetrahydrofuran (THF) and a suitable acylation catalyst is DMAP. Preferably, the peptide is dissolved in dry THF and added at temperatures between about -70 and -90°C, preferably about -80°C, to a mixture containing the therapeutic agent; after addition of DMAP, the cold bath can be removed and the reaction mixture stirred at ambient temperature. The process should be effected over a time period ranging from about 12 to 20 hours, preferably about 16 hours, with stirring at ambient temperature for a period ranging from about 1 to 3 hours, preferably about 2 hours. The peptide bond can also be formed by first mixing the suitable peptide with a coupling agent before the addition of the therapeutic agent in the presence of a polar aprotic solvent and an acylation catalyst.

10 The present invention is further directed to a method of preparing a prodrug of ara-C comprising the steps of: (a) converting the OH groups to high solubility groups; (b) lithiating the product of step (a); (c) bonding a protective peptide group to the N⁴ position of the product of step (b); and (d) converting said high solubility groups to OH groups.

15 Peptide bond formation at the N⁴ position of ara-C is complicated by the intrinsically low nucleophilicity of this amino function; in addition, the presence of three arabinose hydroxyl groups contribute to the low solubility of the compound in common organic solvents. Conversion of the three arabinose hydroxyl groups to groups which increase the solubility of the ara-C in organic solvents is therefore performed as a first step in the above method. The hydroxyl groups can be converted to any high solubility group. Preferably, the hydroxyl groups are converted to O-*tert*-butyldimethylsilyl (OTBDMS) groups. This can be accomplished by stirring ara-C in dry DMF with TBDMSCl and imidazole in the presence of DMAP.

20 In the next step, the product of step (a) is lithiated. This is performed by combining the tri-(*tert*-butyldimethylsilyl) ara-C of step (a) with sufficient quantities of a strong base containing lithium, preferably N-BuLi in hexanes.

30 A protective peptide group is then bonded to N⁴ position of the product of step (b). Examples of suitable peptides for use in this step are given above; other suitable compounds include oxazolinones derived from the peptides Boc-Tyr(Obn)-Aib-OMe, Boc-Tyr(Obn)-Aib, Boc-Gly-Aib and Boc-Aib-Aib. Any

means known in the art can be used to attach these groups to the N⁴ position, such as those described above.


Conversion of the OTBDMS groups, or other high solubility groups, back to hydroxyl groups can be effected by any means known in the art.

5 Preferably, for OTBDMS groups, this is accomplished by mixing the compound containing the protective groups with a mixture of TBAF and THF at ambient temperature for a period of about 15 minutes to 1 hour, preferably 30 minutes, and then is combining this mixture with 3 N HCl and an ET₂O/CH₂Cl₂ mixture at a temperature ranging from about 0° to 21° for a period of about 15 minutes to 1
10 hour, preferably 30 minutes.

Particular embodiments of the invention are provided in the examples below.

As stated previously, the protective peptide group which is bonded to the activating function of the therapeutic agent circumvents the action of various
15 enzymes in cleaving the activating function from the therapeutic agent thereby inactivating the drug. Use of the prodrugs of the present invention having protective peptide groups avoids or substantially delays this result. According to the present invention, the protective peptide groups undergo cyclization in the body which causes the groups to detach from the host therapeutic agent. The result is a
20 heterocycle which corresponds with the peptide group and an activated form of the therapeutic agent. Figure 5 illustrates the heterocycle compounds which result upon intramolecular cyclization of various prodrug formulations prepared according to the methods of the present invention. The rate at which the peptide groups undergo cyclization depends on the particular peptide group which is used and is a first order
25 process, a concept which will be familiar to one skilled in the art. The amount of time it takes for 50% of the prodrug to undergo cyclization in the body, that is--to convert from prodrug to a biologically active drug--is referred to herein as "half-life".

The present invention is further directed to a method of
30 therapeutically treating a patient for an illness comprising the steps of:
(a) employing a prodrug having the formula:



wherein R is a peptide group having between about 1 and 10 amino acid groups, R¹ is selected from the group consisting of a carbon substituent, hydrogen, nitrogen and oxygen, Y is selected from the group consisting of carbon attached to two carbon substituents, two hydrogens or one carbon substituent and one hydrogen, nitrogen attached to two additional carbon substituents, and NH, and Z is a therapeutic agent having an activating function; (b) incorporating said compound in a suitable pharmaceutical carrier; and (c) administering a therapeutically effective amount of said compound incorporated in said carrier to said patient.

As used herein, the term "suitable pharmaceutical carrier" refers to any pharmaceutical carrier that does not have compatibility problems with the prodrug formulation. Suitable carriers include, for example, physiologic saline, water, autologous spinal fluid and dextrose.

As used herein, the term "therapeutically effective amount" refers to that amount of a prodrug formulation incorporated in a suitable pharmaceutical carrier that is targeted to bring about a desired effect, such as inducing remission of leukemia, destroying cancer cells and the like.

A therapeutically effective amount of said compound can be administered by any means known in the art, including but not limited to, intravenously, intraparenterally, intrathecally or orally. It is well within the skill of one practicing in the art to determine what dosage, and the frequency of this dosage, which will constitute a therapeutically effective amount for each individual patient, depending on such factors as the weight of the patient, the type of illness, and the severity of such illness. It is also within the skill of one practicing in the art to select the most appropriate method of administering the prodrug formulation based upon the needs of each patient.

The prodrug compounds of the present invention can be injected subcutaneously at doses of 10 to 200 mg/m² at time periods ranging from 2 to 10 half lives with 4 half lives being the preferred schedule. Intrathecal doses of 10-60 mg/m² can be used with treatment schedules of between 2 and 10 half lives, the preferred being 4 half lives.

EXAMPLES

The following examples are intended to illustrate the invention and should not be construed as limiting the invention in any way.

Example 1

5 The following example provides methods for synthesizing compounds 10, 15, 17 and 19; reference numerals correspond with those in Figures 1 through 4.

2',3',5'-tri-(*tert*-butyldimethylsilyl)-ara-C (4)

10 About 7 g of TBDMSCl, 3.15 g of imidazole and 630 mg of DMAP were added to a solution containing 2.50 g of ara-C in 55 ml of dry DMF. The clear solution was stirred at about 22°C; formation of the product and disappearance of the starting material were monitored by thin layer chromatography (TLC) (MeOH/CHCl₃ 1:9). After about 2 days, the reaction mixture was poured into 200 ml of CH₂Cl₂ and extracted with water (3 x 50 ml). The organic layer was dried
15 over Na₂SO₄, evaporated to dryness and the residue chromatographed on SiO₂ (MeOH/CHCl₃ 1:19) to yield approximately 3.6 g of compound 4 and about 2.16 g of *tetra*-silylated product (N-silylation). The latter compound was dissolved in about 40 ml of THF and treated with 40 ml of a 10% aqueous NH₄OH solution. After about 4 hours of stirring at 22°C, the organic solvent was evaporated and the
20 residue was extracted with CH₂Cl₂ (3 x 25 ml). The combined organic layers were dried over Na₂SO₄, evaporated to dryness and the residue chromatographed on SiO₂ (MeOH/CHCl₃ 1:19) to yield about 1.45 g of compound 4.

Boc-Tyr(OBn)-Aib-OMe (7)

25 A solution containing about 1.5 g of Boc-Tyr(OBn)-OH (5) in 10 ml of dry CH₂Cl₂ was treated at 0°C with about 417 mg of DCC. The mixture was stirred at 0°C for about 5 minutes and treated with a solution containing about 620 mg of Aib-OMe hydrochloride (6) and about 490 mg of NMM in 2 ml of dry DMF. After stirring at 22°C for about 12 hours, the reaction mixture was extracted with a saturated aqueous solution of NH₄Cl. The organic layer was dried over Na₂SO₄,
30 evaporated to dryness, and the residue chromatographed on SiO₂ (EtOAc/hexanes 3:7) to yield about 900 mg of compound 7.

Boc-Tyr(OBn)-Aib-2',3',5'-tri-(*tert*-butyldimethylsilyl)-ara-C (9)

A solution containing about 260 mg of compound 7 and 91.5 mg of LiOH monohydrate in 7.5 ml of THF/H₂O (2:1) was stirred at 22°C for about 3 hours. The organic solvent was evaporated and the aqueous solution was extracted with Et₂O (2 x 10 ml) and then acidified to a pH of less than 1 with 1 N HCl. The mixture was extracted again with Et₂O (3 x 10 ml) and the combined organic extracts were dried over Na₂SO₄ and evaporated to yield about 240 mg of Boc-Tyr(OBn)-Aib-OH. A solution containing about 200 mg of Boc-Tyr(OBn)-Aib-OH in 10 ml of dry CH₃CN was treated at 0°C with 95 mg of DCC and stirred for about 2 hours. After filtration through florisil, the solution was evaporated to dryness. The resulting crude product (8) was dissolved in 2 ml of dry THF and added at -78°C to a mixture of 130 mg of compound 4 and 165 μ M of a 1.5 M solution of N-BuLi in hexanes in 4 ml of dry THF. After addition of about 13 mg of DMAP, the cold bath was removed and the reaction mixture stirred at 22°C for about 2 hours. The solvent was evaporated and 4 ml of water added. After extraction with CH₂Cl₂ (3 x 10 ml), the combined organic layers were dried over Na₂SO₄, filtered and evaporated to dryness. The residue was purified by column chromatography on SiO₂ (EtOAc/hexanes, 1:1) to yield about 285 mg of compound 9.

Tyr(OBn)-Aib-ara-C hydrochloride (10)

A solution containing about 250 mg of compound 9 in 2 ml of THF was treated with about 0.93 ml of a 1 M solution of TBAF in THF, stirred for 40 minutes at 22°C, evaporated to dryness, and the residue chromatographed on SiO₂ (MeOH/CHCl₃ 1:9) to yield about 154 mg of Boc-Tyr(OBn)-Aib-ara-C. A solution containing about 89 mg of this compound in 1.45 ml of CH₂Cl₂ was treated at 0°C with 1.5 ml of 3 N solution of HCl (gas) in Et₂O. The reaction mixture was stirred at 22°C for about 30 minutes, and the precipitate filtered to yield about 81 mg of prodrug compound 10.

Boc-Aib-Aib-OMe (12)

About 200 mg of Et₃N and 100 mg of DMAP were added to a solution containing about 400 mg of Boc-Aib-OH (11) in 10 ml of dry CH₂Cl₂. The clear solution was cooled in an ice bath and treated with a solution of about 408 mg of DCC in 5 ml of dry CH₂Cl₂. The reaction mixture was stirred at about 22°C for

- 15 -

about 12 hours and the resultant slurry filtered through florosil. The filtrate was then evaporated in vacuo and the residue chromatographed on SiO₂ (AcOEt/hexanes 2:3) to yield about 440 mg of compound 12.

Boc-Aib-Aib-2',3',5'-tri-(*tert*-butyldimethylsilyl)-ara-C (14)

5 The procedure used to prepare compound 9 was repeated only using 300 mg of compound 12 instead of compound 7 to yield about 465 mg of compound 14.

Aib-Aib-ara-C hydrochloride (15)

10 The procedure used to prepare compound 10 was repeated using about 250 mg of compound 14 instead of compound 9 to yield 105 mg of prodrug compound 15.

Glc-Aib-ara-C (17)

15 The procedure used to prepare compound 9 was repeated using about 200 mg of compound 16 instead of compound 7 to yield about 468 mg of TBDMS-Glc-Aib-2',3',5'-tri-(*tert*-butyldimethylsilyl)-ara-C. The procedure used to prepare compound 10 was repeated using about 330 mg of this compound instead of compound 9 to yield about 98 mg of prodrug compound 17.

2-Boc-1'-aminoisopropyl-1,3,4-oxadiazol-5-one (18)

20 A solution containing about 160 mg of compound 22 in 4 ml of THF was treated at 22°C with about 144 mg of N,N'-carbonyldiimidazole (CDI). The reaction mixture was stirred for about 3 hours. The solvent was evaporated and the residue chromatographed on SiO₂ (AcOEt/hexanes 2:3) to yield about 152 mg of compound 18.

Boc-Aib-NHNH₂ (21)

25 A solution containing about 570 mg of Boc-Aib-OMe (20) in about 1.5 ml of MeOH was treated at 22°C with about 622 mg of H₂NNH₂ monohydrate. The solution was heated and stirred at 55°C for about 24 hours, and then cooled to about 22°C. The solvent was evaporated in vacuo to yield about 410 mg of crude compound 21.

30 Boc-Aib-2-Azagly-2',3',5'-tri-(*tert*-butyldimethylsilyl)-ara-C (23)

A solution containing about 130 mg of compound 4 in 2 ml of dry THF was cooled to -78°C and treated with about 100 microliters of a 2.5 M solution of N-BuLi in hexanes. After about 5 minutes, a solution containing about

54 mg of CDI in 2 ml of THF was added. A dry ice-acetone bath was removed after 10 minutes, and the reaction mixture was stirred for 1 hour before 96 mg of compound 21 and 13 mg of DMAP were added. After stirring for about 20 hours, the solvent was evaporated and the residue chromatographed on SiO₂ (AcOEt/hexanes 4:1) to yield about 58 mg of compound 4 and 55 mg of compound 23.

Aib-2-Azagly-ara-C hydrochloride (19)

The procedure used to prepare compound 10 was repeated using about 90 mg of compound 23 instead of compound 9 to yield about 34 mg of ara peptide prodrug compound 19.

Example 2

The stability of the ara-C prodrug compounds 10, 15, 17 and 19, prepared according to Example 1, in various reaction media was investigated by NMR and HPLC analyses. The ¹H NMR studies of the cyclization process were performed on a 4 mg/ml solution of prodrug in CD₃OD or D₂O. Sodium acetate (2 mg) or acetic acid (2 microliters) were added neat to the samples to control the pH. The spectra were collected in appropriate time intervals, and the ratio of prodrug to drug was determined by comparing the integration of the H-C (6) on the nucleoside of prodrug and ara-C.

HPLC studies of the cyclization process in plasma were performed on a 4 mg/ml solution of prodrug in plasma. At appropriate time intervals, 25 microliter aliquots were removed and 0.20 ml of CH₃CN was added to precipitate the protein. After centrifugation, about 25 microliters of clear supernatant liquid was injected directly into the HPLC port. The HPLC analysis was performed with a C-18 reverse phase column using an H₂O/CH₃CN (1:1) eluent and the UV detector was set at 250 nm. The relative concentration of ara-C was determined by the relative peak areas. It was found that the rate of release of ara-C was dependent upon the peptide structure and the pH of the medium. The disappearance of characteristic signals of the prodrugs was accompanied by the appearance of signals of ara-C and the corresponding heterocycles. Kinetic analysis showed that the drug was formed following a first order rate law. Figures 6 through 8 plot the percent concentration of prodrug over time. Table 1 below provides the half life (in hours)

for ara-C release of prodrugs 10, 15, 17 and 19 as determined by NMR and HPLC analysis.

Table 1

Half-life (hours) For Release of ara-C
From Prodrugs 10, 15, 17 and 19 in Various Conditions

Entry	Conditions	$t_{1/2}$			
		10	15	17	19
1	CD ₃ OD, 22°C	42	> 1000	360	> 2000
2	CD ₃ OD, 22°C, NaOAc	0.3	1.3	1.4	800
3	CD ₃ OD, 22°C, HOAc	31	> 1000	860	> 2000
4	D ₂ O, 22°C	21	ND	ND	ND
5	Bovine plasma, pH 7.4, 22°C	0.4	0.5	0.4	> 10
6	Human plasma, pH 7.4, 22°C	0.3	0.4	0.3	> 10

ND = not determined

As can be seen from the Table, prodrug 10 was found to have the shortest half life among all of the derivatives. The process of drug release was greatly enhanced in the presence of NaOAc. In the presence of HOAc, however, the intramolecular cyclization was only slightly accelerated, or, in compound 17 actually decelerated. The rate of cyclization of amines 10 and 15 appeared to be dependent on the concentration of free amine versus ammonium salt and should therefore be accelerated in neutral or basic environments. The presence of a bidentate proton acceptor/donor moiety appears to be especially advantageous for the intramolecular carbonyl addition. Upon change of the reaction mixture from CD₃OD to D₂O, compound 10 cyclized about 50% faster.

In general, Compound 17 cyclized slower than compound 10. It is believed that this is a result of the lower nucleophilicity of the hydroxyl versus the amino group. In addition, compound 17 cyclized more slowly in an acidic medium than in a neutral one. While derivative 15 cyclized readily in the presence of NaOAc, its half life was extremely long in the absence of NaOAc or with an excess of HOAc. The azapeptide derivative 19 did not undergo cyclization to release the

drug in neutral or acid conditions, and cyclization was extremely slow even in the presence of NaOAc.

The stability of these compounds in bovine and human plasma was determined by HPLC analysis (Entry 5 and 6 in Table 1). Compounds 10, 15 and 17 were found to cyclize readily in bovine or human plasma. In contrast, compound 19 showed good stability in plasma. No ara-C was detected after 48 hours.

Example 3

The antiproliferation activity of compounds 10, 15, 17 and 19, as compared to ara-C, was tested in an L-1210 cell line growth inhibition assay using various concentrations and continuous exposure. Cell numbers were determined 72 hours after initial drug exposure. Murine L-1210 leukemia cells were grown in suspension using Dulbecco's medium (Gibco/BRL) supplemented with 10% fetal bovine serum (FBS, HyClone), 2 micromols of L-glutamine, 100 U/ml penicillin G sodium, and 100 μ g/ml streptomycin (Gibco/BRL). Cells were grown in a humidified incubator at 37°C under an atmosphere of 95% air and 5% CO₂. Cells were routinely passaged at a 1:5 ratio and found to be free of mycoplasma contamination. The cell growth inhibition in nanograms per milliliter (ng/ml) for each of the compounds tested is given in Table 2 below.

Table 2

L-1210 Cell Growth Inhibition (ng/ml)

Entry	Compound	IC ₅₀	IC ₉₀
1	10	1.3	5
2	15	1.1	3.4
3	17	1.0	3.4
4	19	600	1400
5	ara-C	1.5	4.3

IC₅₀ and IC₉₀ refer to the concentration of compound required to inhibit cell activity by 50 and 90%, respectively. As will be appreciated by one skilled in the art, the lower the IC value, the more potent the drug.

IC₅₀ and IC₉₀ values of compounds 10, 15 and 17 were essentially identical to the ara-C control. This demonstrates that compounds 10, 15 and 17 have comparable efficacy to ara-C. The azapeptide compound, 19, was about 500 more times less toxic in this test.

5

Example 4

The ability of the prodrug compounds to kill human tumor cells was tested, specifically their ability to induce apoptosis in human promyelocytic leukemia HL-60 cells. These cells are known to undergo apoptosis following exposure to ara-C. The ability of the prodrugs to cause internucleosomal DNA fragmentation, a characteristic feature of apoptosis in HL-60 cells, was also investigated. The HL-60 were cultured in essentially the same manner as the L-1210 cells, only using Iscove's modification for the medium. Internucleosomal DNA fragmentation was determined as follows. Following the indicated drug treatments, aliquots of cells (1×10^6) were pelleted by centrifugation at $100 \times g$ for 5 minutes, washed with PBS, solubilized with 20 microliters of lysis buffer (10 mM EDTA, 0.5% sarkosyl, 1 mg/ml proteinase K, 50 mM Tris, pH8), and incubated at 50°C for 1 hour. After incubation, RNaseA (Boehringer Mannheim) was added to a final concentration of 0.33 mg/ml and incubated for an additional hour at 37°C. The lysate was loaded into dry wells of a 1.8% agarose gel, the wells were sealed with low melting point agarose, and the DNA was electrophoresed using Tris-phosphate-EDTA (TPE) running buffer. After electrophoresis, the DNA was stained by immersion of the gel in water containing 1 μ g/ml ethidium bromide (Sigma). The DNA was visualized and photographed using an ultraviolet transilluminator.

25

After a 24 hours exposure to about 10 micromols of ara-C, the appearance of obvious apoptotic bodies was seen in HL-60 cells. Compounds 10, 15 and 17 produced similar results, but compound 19 did not. As can be seen in Figure 9, no significant difference in the efficacy of the active compounds was noted, with a maximum of approximately 25% of the cells treated with ara-C, 10, 15 and 17 exhibiting a frank apoptotic morphology. The formation of apoptotic bodies occurred within a maximal halftime of 4 hours and there was no noticeable

30

difference in the kinetics of apoptosis among ara-C, 10, 15 and 17. Compound 19 produced no obvious increase in apoptosis during the 24 hours observation period.


5 DNA fragmentation of the compounds was tested. HL-60 cells treated with about 10 micromols of ara-C for 4 hours displayed internucleosomal 180-200 base pair DNA fragments. Similar DNA ladders were seen with compounds 10, 15 and 17. Because of the relatively long in vitro half life of compound 19, it was preincubated in serum-free medium for 15 days. As can be seen from Figure 10, preincubation of compound 19 enhanced the apoptotic activity to levels that were slightly less than ara-C. In addition, DNA fragmentation was
10 also seen with preincubated compound 19 which displayed DNA ladders similar ara-C. Thus the efficacy of preincubated compound 19 was similar to that of ara-C.

It will be appreciated that the present invention provides prodrugs of therapeutic agents, and methods of making and using the same, wherein said therapeutic agents are characterized as having an activating function including but
15 not limited to an amino function, a thiol function or a hydroxyl function. These prodrugs circumvent enzymatic removal of the activating function from the therapeutic agent thereby functioning in a timed release manner. In addition, these prodrugs are not toxic to humans.

Whereas, particular embodiments of this invention have been
20 described above for purposes of illustration, it will be evident to those skilled in the art that numerous variations of the details of the present invention may be made without departing from the invention as defined in the claims.

WHAT IS CLAIMED IS:

1. A prodrug having the formula:




wherein R is a peptide group having between about 1 and 10 amino acids, R¹ is selected from the group consisting of a carbon substituent, hydrogen, nitrogen and oxygen, Y is selected from the group consisting of carbon attached to two carbon substituents, two hydrogens or one carbon substituent and one hydrogen, nitrogen attached to a carbon substituent, and NH, and Z is a therapeutic agent having an activating function.

2. The prodrug of Claim 1, wherein said activating function is selected from the group consisting of an amino function, a thiol function, and a hydroxyl function.
3. The prodrug of Claim 2, wherein R is a peptide having between about 1 and 5 amino acid groups.
4. The prodrug of Claim 3, wherein R is a peptide group having 2 amino acid groups.
5. The prodrug of Claim 4, wherein R is an α,α -disubstituted amino acid.
6. The prodrug of Claim 1, wherein R is selected from the group consisting of 2-aminoisobutyric acid, isovaline, 2-methylserine, *tert*-leucine, 2-methylphenylalanine, 2,2-dipropylglycine and β -alanine.
7. The prodrug of Claim 1, wherein Z is selected from the group consisting of antiviral nucleosides, antineoplastic agents and purine and pyrimidine nucleotide drugs.
8. The prodrug formulation of Claim 1, wherein R is selected from the group consisting of 2,2-dialkyl and 2,2-diaryl amino acids, Y is NH and Z is ara-C.
9. A method for preparing a prodrug formulation of a therapeutic agent having an activating function comprising the step of bonding a peptide group to the activating function of said therapeutic agent.
10. The method of Claim 9, further comprising the step of lithiating said therapeutic agent prior to said bonding step.

11. The method of Claim 10, wherein said therapeutic agent further contains hydroxyl groups and further comprising the steps of converting said hydroxyl groups to high solubility groups prior to said lithiating step; and converting said high solubility groups to hydroxyl groups following said bonding step.

12. The method of Claim 11, wherein said peptide group has the general formula:



wherein R¹ is selected from the group consisting of a carbon substituent, hydrogen, nitrogen and oxygen, Y is selected from the group consisting of carbon attached to two carbon substituents, two hydrogens or one carbon substituent and one hydrogen, nitrogen attached to a carbon substituent, and NH, and wherein n is between 1 and 10.

13. The method of Claim 12, wherein said peptide group is selected from the group consisting of

14. The method of Claim 9, wherein said therapeutic agent is selected from the group consisting of antiviral nucleosides, antineoplastic agents and purine and pyrimidine nucleotide drugs.

15. The method of Claim 9, wherein said bonding step is effected by condensing said therapeutic agent with a peptide group in the presence of a polar aprotic solvent and an acylation catalyst.

16. A method of preparing a prodrug of ara-C comprising the steps of:

- a) converting the OH groups to high solubility groups;
- b) lithiating the product of step a);
- c) bonding a peptide group to the N⁴ position of the product of step b); and
- d) converting said high solubility groups to OH groups.

17. The method of Claim 16, wherein said high solubility groups are OTBDMS groups.

18. The method of Claim 17, wherein conversion of said OH groups to OTBDMS groups is performed in the presence of imidazole,

dimethylformamide and dimethylamino puridine; said lithiating step is achieved by mixing the product of step (a) with sufficient quantities of N-BuLi in hexanes; said bonding step is accomplished by mixing the product of step (b) with a


peptide group of the formula $\left(\begin{array}{c} \text{R}^1 \\ | \\ \text{C} - \text{N} - \text{Y} - \text{C} \end{array} \begin{array}{c} \text{O} \\ || \end{array} \right)_n$; wherein R¹ is selected from the group consisting of a carbon substituent, hydrogen, nitrogen and oxygen, Y is selected from the group consisting of carbon attached to two carbon substituents, two hydrogens or one carbon substituent and one hydrogen, nitrogen attached to two additional carbon substituents, and NH, and n is between 1 and 10; and conversion of said OTBDMS groups to OH groups is performed by mixing the product of step (c) with tetrabutylammonium fluoride and tetrahydrofuran, and then mixing with 3 N HCl and an Et₂O/CH₂Cl mixture.

19. The method of Claim 18, wherein said protective peptide group is selected from the group consisting of 2-aminoisobutyric acid, isovaline, 2-methylserine, *tert*-leucine, 2-methylphenylalanine, 2,2-dipropylglycine and β-alanine.

20. The method of Claim 19, wherein said protective peptide group is 2-aminoisobutyric acid.

21. A method of therapeutically treating a patient comprising the steps of:

a) employing a prodrug having the formula:



wherein R is a peptide group having between about 1 and 10 amino acids, R¹ is selected from the group consisting of a carbon substituent, hydrogen, nitrogen and oxygen, Y is selected from the group consisting of carbon attached to two carbon substituents, two hydrogens or one carbon substituent and one hydrogen, nitrogen attached to a carbon substituent, and NH, and Z is a therapeutic agent having an activating function;

- 24 -

- b) incorporating said compound in a suitable pharmaceutical carrier; and
- c) administering a therapeutically effective amount of said compound incorporated in said carrier to a patient.

22. The method of Claim 21 wherein said patient has an illness selected from the group consisting of leukemia, lymphoma and neoplastic meningitis.

23. The method of Claim 21 wherein said carrier is selected from the group consisting of physiologic saline, dextrose, water and autologous spinal fluid.


24. The method of Claim 21 including administering said compound incorporated in said carrier to a patient subcutaneously.

25. The method of Claim 21, including administering said compound incorporated in said carrier to a patient intrathecally.

26. The method of Claim 21, including administering said compound incorporated in said carrier to a patient intravenously.

27. The prodrug of Claim 1 further characterized as having a half-life in a patient of between about 10 minutes and 10 days.

28. A method of administering a prodrug having the formula:



wherein R is a peptide group having between about 1 and 10 amino acids, R¹ is selected from the group consisting of a carbon substituent, hydrogen, nitrogen and oxygen, Y is selected from the group consisting of carbon attached to two carbon substituents, two hydrogens or one carbon substituent and one hydrogen, nitrogen attached to a carbon substituent, and NH, and Z is a therapeutic agent having an activating function comprising the step of providing said prodrug to a patient every 2 to 10 half lives.

1/10




FIGURE 1

2/10




FIGURE 2

3/10




FIGURE 3

4/10




FIGURE 4

5/10




FIGURE 5

6/10




FIGURE 6

7/10




FIGURE 7

8/10




FIGURE 8

9/10




FIGURE 9

10/10




FIGURE 10

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/11817

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) : A61K 38/04; A01N 43/54; C07K 5/00

US CL : 530/328-331; 514/15-19, 269; 544/304

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 530/328-331; 514/15-19, 269; 544/304

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

USPATFUL, WPIDS, CAPLUS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BALAJTHY, Z. et al. Syntheses and functional evaluation of a peptide derivative of 1- β -D-arabinofuranosylcytosine. J. Med. Chem. 1992, Vol. 35, No. 18, pages 3344-3349, see abstract and page 3344.	1-5 and 7
X	CHAKRAVARTY, P. K. et al. Plasmin-activated prodrugs for cancer chemotherapy. 1. Synthesis and biological activity of peptidylacivicin and peptidylphenylenediamine mustard. J. Med. Chem. 1983, Vol. 26, No. 5, pages 633-638, see abstract and pages 633-34 (schemes 1 and 2).	1-5 and 7

☒ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"A" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

11 SEPTEMBER 1997

Date of mailing of the international search report

10 OCT 1997

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BENNETT CELSA

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US97/11817

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5,087,616 A (MYERS ET AL.) 11 February 1992, see abstract, columns 9-12 and claims.	1-8
A	US 4,479,898 A (GILVARG ET AL.) 30 October 1984, see abstract and columns 1-10.	1-8

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/11817

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
1-8 and ara-c as therapeutic species

Remark on Protest

☐

The additional search fees were accompanied by the applicant's protest.

☐

No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US97/11817

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-8, drawn to a prodrug.

Group II, claims 9-20, drawn to a method of preparing a prodrug formulation, especially ara-c.

Group III, claims 21-28, drawn to a method of therapeutically treating a patient and administering a prodrug.

AND

Various disclosed and claimed therapeutic species:

- I. ara-c
- II. hydroxyurea
- III. thioguanine
- IV. mitomycin c
- V. zalcitabine
- VI. didanosine
- VII. zidovudine
- VIII. stavudine

SUM: 24 inventions

and it considers that the International Application does not comply with the requirements of unity of invention (Rules 13.1, 13.2 and 13.3) for the reasons indicated below:

The inventions listed as Groups I-III do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Unity of invention is lacking between Groups I-III since there is no technical relationship between the various solutions since these groups do not share a technical feature since the peptide prodrugs within the scope of claim 1 are known in the art. (e.g. See Chakravarty, J. Med. Chem. 1988, Vol. 26, pages 633-638 and Balajthy et al., J. Med.Chem. 1992, Vol. 35, pages 3344-3349).

In the present case unity of invention for the Markush groupings of claims 1, 9, 21 and can only be acknowledged if it can be shown that:

- I) all alternatives have a common activity; AND
- II) an inventive, common structural element.

In the present instance, the formula of claim 1 lack a common structural elements since there is virtually no fixed structural element which may be regarded as representing the inventive structural element. Further, the therapeutic agent comprising the peptide prodrug lacks a common structural core to elicit a common activity. The cited references above describe different therapeutics with varying structure and activity and various disclosed and claimed therapeutic species are mentioned:

- I. ara-c II. hydroxyurea III. thioguanine IV. mitomycin c V. zalcitabine VI. didanosine VII. zidovudine VIII. stavudine